Keywords: لوپیناویر; ASD; amorphous solid dispersions; CA; cellulose acetate; CAP; cellulose acetate phthalate; DL; drug loading; DSC; differential calorimetry scanning; EC; ethylcellulose; EUD; Eudragit® RL PO; HPMC; hydroxypropylmethylcellulose (hypromellose); HPMCAS; hydr
مقالات ISI لوپیناویر (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: لوپیناویر; in vitro/in vivo correlations (IVIVC); hepatic transport; hepatic metabolism; hepatic clearance; hepatocytes; HIV/AIDS; membrane transport; metabolism; organic anion-transporting polypeptide transporters; APV; amprenavir; ATV; atazanavir; CHO; Chinese h
Keywords: لوپیناویر; Metered-dose transdermal spray; Lopinavir; Microneedles; Skin microportion; Permeation enhancement; Kollidon® VA 64
Keywords: لوپیناویر; 3TC; Lamivudine; ABC; Abacavir; ARV; Antiretroviral; ATV; Atazanavir; AZT; Zidovudine; d4T; Stavudine; DRV; Darunavir; EFV; Efavirenz; FTC; Emtricitabine; L&D; Labor and delivery; LOQ; Limit of quantification; LPV; Lopinavir; M8; NFV hydroxy-tert-butylami
Keywords: لوپیناویر; Lopinavir; Unbound fraction; Ultrafiltration; Nonspecific binding; UPLC–MS/MS
Keywords: لوپیناویر; Pullulan acetate; Lopinavir; Nanoparticles; Physical characterization; Pharmacokinetic studies; Tissue distribution
Keywords: لوپیناویر; SULLE; Sugaring out; Sample preparation; Liquid chromatography; Lopinavir; Ritonavir; Bioanalysis; SALLE;
Keywords: لوپیناویر; MAFP (methyl arachidonyl fluoro phosphonate); Progesterone; BMP (bismonoacylglycerophosphate); Sterol transporter NPC-1; PLRP2 (pancreatic lipase-related protein 2); Desmosterol; Cholesterol epoxide; MAFP; methyl arachidonyl fluoro phosphonate; PROG; prog
HIV aspartyl protease inhibitors modify the percentage of activated leukocytes, as well as serum levels of IL-17A and NO during experimental leishmaniasis
Keywords: لوپیناویر; Leishmania; Lopinavir; Atazanavir; Lymphocytes; Nitric Oxide; Cytokines;
The relevance of co-amorphous formulations to develop supersaturated dosage forms: In-vitro, and ex-vivo investigation of Ritonavir-Lopinavir co-amorphous materials
Keywords: لوپیناویر; RTV; Ritonavir; LPV; Lopinavir; RLQC 1:1; co-amorphous Ritonavir-Lopinavir prepared by quench cooling at 1:1â¯M ratio; RLQC 1:2; co-amorphous Ritonavir-Lopinavir prepared by quench cooling at 1:2â¯M ratio; RLQC 2:1; co-amorphous Ritonavir-Lopinavir prep
Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells and show anti-amastigote activity
Keywords: لوپیناویر; Trypanosoma cruzi; HIV-PI; Nelfinavir; Lopinavir; Cellular interaction; Amastigotes;
LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation
Keywords: لوپیناویر; Vascular smooth muscle cells; ZMPSTE24; Prelamin A; Senescence; Osteogenic transdifferentiation; Atherosclerosis; ALP; alkaline phosphatase; ATV; atazanavir; DRV; darunavir; HIV; human immunodeficiency virus; LPV; lopinavir; M/R; maraviroc/raltegravir; PB
Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction
Keywords: لوپیناویر; PI; protease inhibitors; ROS; reactive oxygen species; HO-1; heme oxygenase-1; CO; carbon monoxide; CORM2; carbon monoxide releasing molecule-2; iCORM2; inactivated carbon monoxide releasing molecule-2; CM-H2DCFDA; 5-(and-6)-chloromethyl-2,7-dichlorodihyd
Metabolic abnormalities and cardiovascular risk in HIV-infected cohort of patients treated with protease inhibitors
Keywords: لوپیناویر; cART; Cardiovascular risk in HIV patients; Lipid parameters; Atazanavir; Lopinavir
Development and validation of a stability indicating HPLC method for the simultaneous analysis of lopinavir and ritonavir in fixed-dose combination tablets
Keywords: لوپیناویر; Degradation; High-performance liquid chromatography; Lopinavir; Method validation; Ritonavir
Enhanced Boosting of Oral Absorption of Lopinavir Through Electrospray Coencapsulation with Ritonavir
Keywords: لوپیناویر; boosting; oral absorption improvement; coaxial electrospray deposition; enteric-coated particle; lopinavir; ritonavir
Simultaneous determination of lopinavir and three ester prodrugs by LC-MS/MS in lysates of BeWo cells
Keywords: لوپیناویر; BSA; bovine serum albumin; DLPV; diglycolic acid monoester of lopinavir; DPBS; Dulbecco's phosphate buffered saline; GLPV; glutaric acid monoester of lopinavir; LPV; lopinavir; MRP2; multidrug resistance-associated protein 2; Pgp; P-glycoprotein; RTV; rit
P1 and P1′ para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: Structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease
Keywords: لوپیناویر; HIV/AIDS; HIV-1 protease; Multidrug-resistance; Protease inhibitors; Lopinavir; Virtual screening
Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir
Keywords: لوپیناویر; Lopinavir; LPV; Dipeptide prodrug; Uptake; Transport; Permeability; P-gp; MRP2 and metabolism
Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease
Keywords: لوپیناویر; HIV-1 protease; Drug resistance; Drug design; Crystallography; Lopinavir;
Comparative analysis of ER stress response into HIV protease inhibitors: Lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway
Keywords: لوپیناویر; APV; Amprenavir; ARE; antioxidant response; ATV; Atazanavir; cART; Combination antiretroviral therapy; DRV; Darunavir; FDA; Food and Drug Administration; IDV; Indinavir; LDH; lactate dehydrogenase; LPV; Lopinavir; NAC; N-acetyl-L-cysteine; NFV; Nelfinavir
High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba
Keywords: لوپیناویر; ART; antiretroviral therapy; CI; confidence interval; NRTI; nucleoside reverse transcriptase inhibitor; NNRTI; non-nucleoside RTI; PI; protease inhibitor; FCR; full-class resistance; CRF; circulating recombinant form; HIV; human immunodeficiency virus; MD
Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavir and Ritonavir Active pharmaceutical ingredients by LC/MS/MS using electrospray ionization
Keywords: لوپیناویر; Methyl methanesulfonates; Ethyl methanesulfonates; LC/MS/MS; Lopinavir; Ritonavir
Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting
Keywords: لوپیناویر; Lopinavir; Anti-Retroviral Therapy; Solid lipid nanoparticles (SLN); Intestinal lymphatic targeting; Gut associated lymphoid tissue (GALT)
Meta-análisis sobre la eficacia de la estrategia de monoterapia con inhibidores de la proteasa potenciados en pacientes VIH+
Keywords: لوپیناویر; Inhibidores de proteasa; Meta-análisis; Ritonavir potenciado; Lopinavir; Darunavir; Ritonavir; HIV protease inhibitors; Meta-Analysis; Boosted ritonavir; Lopinavir; Darunavir; Ritonavir;
Lopinavir co-induces insulin resistance and ER stress in human adipocytes
Keywords: لوپیناویر; HIV-protease inhibitors; Lopinavir; Insulin resistance; ER stress; IRS1; eIF2 alpha;
Rapid, simultaneous determination of lopinavir and ritonavir in human plasma by stacking protein precipitations and salting-out assisted liquid/liquid extraction, and ultrafast LC–MS/MS
Keywords: لوپیناویر; Salting-out; Ultrafast liquid chromatography; Sample preparation; High throughput; Lopinavir; Ritonavir
Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs
Keywords: لوپیناویر; Cytochrome P450 3A; Ritonavir; Lopinavir
Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC–ESI-MS/MS for bioequivalence study in Indian subjects
Keywords: لوپیناویر; Lopinavir; Ritonavir; UPLC–ESI-MS/MS; High throughput; Bioequivalence
Cholesterol levels in HIV–HCV infected patients treated with lopinavir/r: Results from the SCOLTA project
Keywords: لوپیناویر; Antiretroviral therapy; Lopinavir; HIV; Atherosclerosis; HCV; Cardiovascular diseases; Cholesterol; Lipids
Development and validation of dissolution test for lopinavir, a poorly water-soluble drug, in soft gel capsules, based on in vivo data
Keywords: لوپیناویر; Lopinavir; Dissolution; Validation; In vitro–in vivo correlation
Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors
Keywords: لوپیناویر; SARS; Proteinase; MD simulations; Ritonavir; Lopinavir
Peptide prodrugs: Improved oral absorption of lopinavir, a HIV protease inhibitor
Keywords: لوپیناویر; Lopinavir; LVR; VL; VVL; GVL; Peptide; Prodrug
Impurity profile study of lopinavir and validation of HPLC method for the determination of related substances in lopinavir drug substance
Keywords: لوپیناویر; Lopinavir; Related substances; Characterization; Gradient RP-HPLC; Method development and validation
A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations
Keywords: لوپیناویر; HIV-1; Drugs; Second line; Synthesis; Prices; Efavirenz; Tenofovir Disoproxil Fumarate; TDF; Emtricitabine; FTC; Ritonavir; Lopinavir; Kaletra; Atazanavir
Lopinavir/ritonavir and rifampin: is coadministration possible?
Keywords: لوپیناویر; lopinavir; ritonavir; rifamycins; rifampin; rifampicin; rifabutin; drug interactions
Effects of lopinavir–ritonavir combined therapy during the rat pregnancy: Morphological and biochemical aspects
Keywords: لوپیناویر; Lopinavir; Ritonavir; Toxicology; Pregnancy; Rat
Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry
Keywords: لوپیناویر; Cerebral spinal fluid; Ultrafiltrate; Protein binding; Lopinavir; Chromatography coupled to mass spectrometry;
Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay
Keywords: لوپیناویر; Kaletra®; Ritonavir; Lopinavir; PBMC; Protein binding; LC/MS/MS
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors
Keywords: لوپیناویر; Lopinavir; HIV resistance; Pharmacokinetics; Inhibitory quotient; Virological response;
Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model
Keywords: لوپیناویر; Placental transfer; Ex vivo perfused human cotyledon; Human immunodeficiency virus; Antiretroviral; Protease inhibitor; Lopinavir; Ritonavir
Validation and application of a high-performance liquid chromatography–tandem mass spectrometric method for simultaneous quantification of lopinavir and ritonavir in human plasma using semi-automated 96-well liquid–liquid extraction
Keywords: لوپیناویر; Atmospheric pressure chemical ionization; Human immunodeficiency virus; Human plasma; Kaletra; High-performance liquid chromatography–tandem mass spectrometry; Lopinavir; Ritonavir
Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV
Keywords: لوپیناویر; HIV; Protease inhibitor; Lopinavir; HIV resistance; Imidazolidine-2,4-dione
Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir
Keywords: لوپیناویر; 3TC; lamivudin; ABC; abacavir; AZT; azidothymidin (zidovudin); d4Tstavudin; ddC; dideoxycytidin (zalcitabin); ddI; dideoxyinosin (didanosin); EFV; efavirenz; HAART; highly active antiretroviral therapy; IDV; indinavir; LPV; lopinavir; LPV/r; combination o
Lopinavir/ritonavir combination and total/HDL cholesterol ratio
Keywords: لوپیناویر; Drug Monitoring; Hyperlipidemia; Lopinavir;
Effets indésirables induits par les traitements antirétroviraux
Keywords: لوپیناویر; ABC; abacavir; APV; amprénavir; ARV; antiretroviral; ASAT; aspartate aminotransférase; ATZ; atazanavir; AZT; zidovudine; ddI; didanosine; d4T; stavudine; EFV; éfavirenz; EI; effet indésirable; FTC; emtricitabine; HDL; lipoprotéine de haute densité;
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
Keywords: لوپیناویر; Protease inhibitors; Non-nucleoside reverse transcriptase inhibitors; PBMCs; Peripheral blood mononuclear cells; HPLC-MS/MS; Indinavir; Amprenavir; Saquinavir; Ritonavir; Nelfinavir; Lopinavir; Atazanavir; Efavirenz; Nevirapine;